Xeris Biopharma Holdings Inc (XERS)
3.075
+0.04
(+1.15%)
USD |
NASDAQ |
Nov 22, 13:40
Xeris Biopharma Holdings Debt to Equity Ratio: -8.166 for Sept. 30, 2024
Debt to Equity Ratio Chart
Historical Debt to Equity Ratio Data
| Date | Value |
|---|---|
| September 30, 2024 | -8.166 |
| June 30, 2024 | -11.95 |
| March 31, 2024 | -25.02 |
| December 31, 2023 | -28.15 |
| September 30, 2023 | 49.27 |
| June 30, 2023 | 13.80 |
| March 31, 2023 | 6.244 |
| December 31, 2022 | 4.14 |
| September 30, 2022 | 2.516 |
| June 30, 2022 | 1.867 |
| March 31, 2022 | 1.430 |
| December 31, 2021 | 0.9248 |
| September 30, 2021 | -35.64 |
| June 30, 2021 | 4.398 |
| Date | Value |
|---|---|
| March 31, 2021 | 1.966 |
| December 31, 2020 | 2.578 |
| September 30, 2020 | 8.328 |
| June 30, 2020 | 4.490 |
| March 31, 2020 | 2.161 |
| December 31, 2019 | 4.039 |
| September 30, 2019 | 1.331 |
| June 30, 2019 | 0.4332 |
| March 31, 2019 | 0.3001 |
| December 31, 2018 | 0.4229 |
| September 30, 2018 | 0.3327 |
| June 30, 2018 | 0.1662 |
| March 31, 2018 | 0.5495 |
| December 31, 2017 | 0.00 |
Debt to Equity Ratio Definition
The debt to equity ratio measures the (Long Term Debt + Current Portion of Long Term Debt) / Total Shareholders' Equity. This metric is useful when analyzing the health of a company's balance sheet.
Debt to Equity Ratio Range, Past 5 Years
-35.64
Minimum
Sep 2021
49.27
Maximum
Sep 2023
-0.0394
Average
2.339
Median
Debt to Equity Ratio Benchmarks
| Zevra Therapeutics Inc | 0.8443 |
| NovaBay Pharmaceuticals Inc | 0.0476 |
| Palatin Technologies Inc | -- |
| iBio Inc | -- |
| Theriva Biologics Inc | -- |
Debt to Equity Ratio Related Metrics
| Total Assets (Quarterly) | 321.10M |
| Total Liabilities (Quarterly) | 349.43M |
| Shareholders Equity (Quarterly) | -28.32M |
| Current Ratio | 1.789 |
| Net Debt Paydown Yield | -2.03% |